While biopharma innovators failed to win major changes to the inter partes review (IPR) patent challenge proceeding this year, several members of the House have indicated that they are willing to continue the battle in the next Congress.
Ten US House Representatives from New York sent a Dec. 5 letter to US Patent and Trademark Office...




